Celularity Inc. faces potential delisting for failing to file Q2 2024 Form 10-Q; aims to regain compliance by Sept 6 with possible extension to Oct 14.

Celularity Inc., a regenerative medicine firm, has been notified by Nasdaq for non-compliance due to failure to file Form 10-Q for Q2 2024. The company aims to regain compliance by submitting a plan by Sept 6, with potential extension to Oct 14 if approved. Despite the trading of its common stock and warrants continuing, there's no guarantee of regaining compliance or meeting other Nasdaq requirements.